No Data
Sinolink: Major policies have been released, innovation remains the most important direction. The pharmaceutical and healthcare Industry has entered a performance window, focusing on reversal expectations.
The market has entered the window period for annual and quarterly reports, and it is recommended to actively pay attention to the fundamental Bearish clearance of left-side symbols (such as some Medical Devices, Traditional Chinese Medicine, pharmacies, chain Medical, CXO, etc.) and the implementation of centralized procurement policies.
Humanwell Healthcare (600079.SH): Celecoxib capsules have obtained the pharmaceutical registration certificate.
On January 6, Gelonghui reported that Humanwell Healthcare (600079.SH) announced that its holding subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd. (referred to as "Yichang Humanwell", in which the company Holds 80% of the shares), recently received the Drug Registration Certificate for Celecoxib Capsules approved and issued by the National Medical Products Administration. The approved indications for Celecoxib Capsules are: (1) for the relief of symptoms and signs of osteoarthritis (OA); (2) for the relief of symptoms and signs of adult rheumatoid arthritis (RA); (3) for the treatment of adult acute pain (AP); (4) for the relief of symptoms and signs of ankylosing spondylitis.
Is Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Latest Stock Performance A Reflection Of Its Financial Health?
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Humanwell Healthcare (600079.SH): Yichang Industrial Investment Group collectively controls 12.35% of the voting shares of the company.
On December 12, Gelonghui reported that Humanwell Healthcare (600079.SH) announced that this equity change involves a 5% or more non-first largest Shareholder, Yichang Chanto Holdings Group Co., Ltd. (referred to as "Yichang Chanto Group"), whose wholly-owned subsidiary is Yichang Chanto Industry Research and Development Co., Ltd. (referred to as "Industry Research Company"), signing the agreement with Xinshenglibao Private Equity Co., Ltd. (referred to as "Xinshenglibao"), CHINA CINDA Asset Management Co., Ltd. (referred to as "CHINA CINDA"), and Yichang Hi-tech Capital Investment Management Co., Ltd. (referred to as "Yichang Hi-tech Capital").
Humanwell Healthcare (600079.SH): Director Wang Xuehai has cumulatively reduced his shareholding by 0.89 million shares of the company.
On December 10, Glonghui reported that Humanwell Healthcare (600079.SH) announced that as of the date of this announcement, the Shareholding plan's Range has expired, and Director Wang Xuehai has cumulatively reduced his holdings by 0.89 million shares, accounting for 0.05% of the company's total equity.
The Market Doesn't Like What It Sees From Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Earnings Yet
